Clinical trial opportunities in transfusion medicine: Proceedings of a national heart, lung, and blood institute state-of-the-science symposium

Transfusion Medicine Reviews

Volumn 24, Issue 4, 2010, Pages 259-285

  Blajchman, Morris A ^a   Glynn, Simone A ^b   Josephson, Cassandra D ^c   Kleinman, Steve H ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPLASTY; BLOOD; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; BRAIN INJURY; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; ENCEPHALOMALACIA; ERYTHROCYTE TRANSFUSION; FEASIBILITY STUDY; HEART INFARCTION; HEART SURGERY; HEMOSTASIS; HUMAN; LOW BIRTH WEIGHT; NATIONAL HEALTH ORGANIZATION; OPERATING ROOM; POSTOPERATIVE HEMORRHAGE; REVIEW; SUBARACHNOID HEMORRHAGE; SURGICAL TECHNIQUE; THROMBOCYTE; THROMBOCYTE TRANSFUSION; TRAUMATIC BRAIN INJURY;

BLOOD PLATELETS; BLOOD TRANSFUSION; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; DISEASE TRANSMISSION, INFECTIOUS; HUMANS; INFANT, NEWBORN; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (U.S.); NEONATOLOGY; PEDIATRICS; PLATELET TRANSFUSION; PREVENTIVE MEDICINE; REGENERATIVE MEDICINE; RESEARCH; UNITED STATES;

EID: 77956821586     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2010.05.002     Document Type: Review

References (76)

1. Blajchman M.A., Slichter S.J., Heddle N.M., et al. New strategies for the optimal use of platelet transfusions. Hematology. Am Soc Hematol Educ Program 2008, 198-204.
2. Stanworth S.J., Hyde C., Brunskill S., et al. Platelet transfusion prophylaxis for patients with haematological malignancies. Where to now?. Br J Haematol 2005, 131:588-595.
3. Slichter S.J., Kaufman R.M., Assman S.F., et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Eng J Med 2010, 362:600-613.
4. Stanworth S.J., Dyer C., Choo L., et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (Trial of Platelet Prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfus Med Rev 2010, 24:163-171.
5. Wandt H., Schaefer-Eckart K., Pilz B., et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukemia: Preliminary results of a randomized multicenter study after enrollment of 175 patients. Blood 2009, 113(Supplement):289a-290a. (abstract).
6. Kleinman S., Dumont L.J., Tomasulo P., et al. The impact of discontinuation of 7-day storage of apheresis platelets (PASSPORT) on recipient safety: An illustration of the need for proper risk assessment. Transfusion 2009, 49:903-912.
7. McCullough J., Vesole D.H., Benjamin R.J., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT Trial. Blood 2004, 104:1534-1541.
8. AuBuchon J.P., Herschel L., Roger J., et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005, 45:1335-1341.
9. Klein H.G., Glynn S.A., Ness P.M., et al. Research opportunities for pathogen reduction/inactivation of blood components: Summary of an NHLBI workshop. Transfusion 2009, 49:1262-1268.
10. Lacroix J., Hébert P.C., Hutchison J.S., et al. Transfusion strategies for patients in pediatric intensive care units. N Eng J Med 2007, 356:1609-1619.
11. Andrew M., Vegh P., Caco C., et al. A randomized, controlled trial of platelet transfusions in thrombocytopenic premature infants. J Pediatr 1993, 123:286-291.
12. Murray N.A., Howarth L.J., McCloy M.P., et al. Platelet transfusion in the management of severe thrombocytopenia in neonatal intensive care unit patients. Transfus Med 2002, 12:35-41.
13. Josephson C.D., Su L.L., Christensen R.D., et al. Platelet transfusion practices among neonatologists in the United States and Canada: results of a survey. Pediatrics 2009, 123:278-285.
14. Stanworth S.J., Clarke P., Watts T., et al. Prospective, observational study of outcomes in neonates with severe thrombocytopenia. Pediatrics 2009, 124:e826-e834.
15. Kirpalani H., Whyte R.K., Andersen C., et al. The Premature Infants in Need of Transfusion (PINT) study: A randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. J. Pediatr. 2006, 149:301-307.
16. Whyte R.K., Kirpalani H., Asztalos E.V., et al. Neurodevelopmental outcome of extremely low birth weight infants randomly assigned to restrictive or liberal hemoglobin thresholds for blood transfusion. Pediatrics 2009, 123:207-213.
17. Bell E.F., Strauss R.G., Widness J.A., et al. Randomized trial of liberal versus restrictive guidelines for red blood cell transfusion in preterm infants. Pediatrics 2005, 115:1685-1691.
18. Abdel-Wahab O.I., Healy B., Dzik W.H. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion 2006, 46:1279-1285.
19. Segal J.B., Dzik W.H. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: An evidence-based review. Transfusion 2005, 45:1413-1425.
20. Dzik W.H. The James Blundell Award Lecture 2006: Transfusion and the treatment of haemorrhage: Past, present and future. Transfus Med 2007, 17:367-374.
21. Alexander K.P., Chen A.Y., Wang T.Y., et al. Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. Am Heart J 2008, 155:1047-1053.
22. Doyle B.J.R., Gastineau D.A., Holmes D.R. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention. J Am Coll Cardiol 2009, 53:2019-2027.
23. Hébert P.C., Wells G., Blajchman M.A., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion requirements in critical care investigators, Canadian critical care trials group. N Engl J Med 1999, 340:409-417.
24. Hébert P.C., Yetisir E., Martin C., et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases?. Crit Care Med 2001, 29:227-234.
25. Klein H.G., Anstee D.J. Mollison's blood transfusion in clinical medicine 2005, Blackwell Publishing, Oxford, UK. ed 11.
26. Stansbury L.G., Dutton R.P., Stein D.M., et al. Controversy in trauma resuscitation: Do ratios of plasma to red blood cells matter?. Transfus Med Rev 2009, 23:255-265.
27. Alport E.C., Callum J.L., Nahirniak S., et al. Cryoprecipitate use in 25 Canadian hospitals: Commonly used outside of the published guidelines. Transfusion 2008, 48:2122-2127.
28. Callum J.L., Karkouti K., Lin Y. Cryoprecipitate: The current state of knowledge. Transfus Med Rev 2009, 3:177-188.
29. Karisson M., Ternström L., Hyllner M., et al. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: A prospective observational study. Transfusion 2008, 48:2152-2158.
30. Karisson M., Ternström L., Hyllner M., et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomized pilot study. Thromb. Haemost. 2009, 102:137-144.
31. Karkouti K., Wijeysundera D.N., Beattie W.S., et al. Variability and predictability of large-volume red blood cell transfusion in cardiac surgery: A multicenter study. Transfusion 2007, 47:2081-2088.
32. Busund R., Koukline V., Utrobin U., et al. Plasmapheresis in severe sepsis and septic shock: a prospective, randomized, controlled trial. Intens Care Med 2002, 28:1434-1439.
33. Reeves J.H., Butt W.W., Shann F., et al. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in sepsis study group. Crit Care Med. 1999, 27:2096-2104.
34. Nguyen T.C., Han Y.Y., Kiss J.E., et al. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children and thrombocytopenia-associated multiple organ failure. Crit Care Med 2008, 36:2878-2887.
35. Flowers M.E., Apperley J.F., van Besien K., et al. A multicenter prospective phase 2 randomised study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008, 112:2667-2674.
36. Voss C.Y., Fry T.J., Coppes M.J., et al. Extending the horizon for cell-based immunotherapy by understanding the mechanisms of action of photopheresis. Transfus Med Rev 2010, 24:22-32.
37. Greinix H.T., Pohlreich D., Maalouf J., et al. A single-center pilot validation study of a new chronic GVHD skin scoring system. Biol Blood Marrow Transpl 2007, 13:715-723.
38. Martin P.J., Weisdorf D., Przepiorka D., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: VI. Design of clinical trials working group report. Biol Blood Marrow Transpl. 2006, 12:491-505.
39. Hirano T., Yamanaka J., Iimuro Y., et al. Long-term safety of autotransfusion during hepatectomy for hepatocellular carcinoma. Surg Today 2005, 35:1042-1046.
40. Davis M., Sofer M., Gomez-Marin O., et al. The use of cell salvage during radical retropubic prostatectomy: Does it influence cancer recurrence?. BJU Int 2003, 91:474-476.
41. Gray C.L., Amling C.L., Polston G.R., et al. Intraoperative cell salvage in radical retropubic prostatectomy. Urology 2001, 58:740-745.
42. Yang H., Lee J., Seed C.R., et al. Can blood transfusion transmit cancer? A literature review. Transfus Med Rev 2010, 24:235-243.
43. Berger J.S., Frye C.B., Harshaw Q., et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: A multicenter analysis. J Am Coll Cardiol 2008, 52:1693-1701.
44. Maltais S., Perrault L.P., Do Q.B. Effect of clopidogrel on bleeding and transfusions after off-pump coronary artery bypass graft surgery: Impact of discontinuation prior to surgery. Eur J Cardiothorac Surg 2008, 34:127-131.
45. Ebrahimi R., Dyke C., Mehran R., et al. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: The ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2009, 53:1965-1972.
46. Shander A., Perelman S. The long and winding road of acute normovolemic hemodilution. Transfusion 2006, 46:1075-1079.
47. Segal J.B., Blasco-Colmenares E., Norris E.J., et al. Preoperative acute normovolemic hemodilution: A meta-analysis. Transfusion 2004, 44:632-644.
48. Jamagin W.R., Gonen M., Maithel S.K., et al. A prospective randomized trial of acute normovolemic hemodilution compared to standard intraoperative management in patients undergoing major hepatic resection. Ann Surg 2008, 48:360-369.
49. Bennett J., Haynes S., Torella F., et al. Acute normovolemic hemodilution in moderate blood loss surgery: A randomized control trial. Transfusion 2006, 46:1097-1103.
50. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997, 337:1861-1869. TRAP Study Group.
51. Slichter S.J., Davis K., Enright H., et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005, 105:4106-4114.
52. Hanson S.R., Slichter S.J. Platelet kinetics in patients with bone marrow hypoplasia: Evidence for a fixed platelet requirement. Blood 1985, 66:1105-1109.
53. Asano H., Lee C.Y., Fox-Talbot K., et al. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007, 15:1174-1182.
54. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010, Mirasol Clinical Evaluation Study Group, (Epub ahead of print June 2010).
55. Snyder E., McCullough J., Slichter S.J., et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet a light for pathogen inactivation: The SPRINT trial. Transfusion 2005, 45:1864-1875.
56. Hei D.J., Grass J., Lin L., et al. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet a light. Transfusion 1999, 39:239-248.
57. Fiebig E., Hirschkorn D.F., Maino V.C., et al. Assessment of donor T-cell function in cellular blood components by the CD69 induction assay: Effects of storage, gamma radiation, and photochemical treatment. Transfusion 2000, 40:761-770.
58. Bohlius J., Schmidlin K., Brilliant C., et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 2009, 373:1532-1542.
59. Ludwig H., Crawford J., Osterborg A., et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009, 27:2838-2847.
60. Pedrazzoli P., Farris A., Del Prete S., et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008, 26:1619-1625.
61. Bastit L., Vandebroek A., Altintas S., et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008, 26:1611-1618.
62. Eder A.F., Dy B.A., Kennedy J.M., et al. The American Red Cross donor hemovigilance program: Complications of blood donation reported in 2006. Transfusion 2008, 48:1809-1819.
63. Eder A.F., Hillyer C.D., DY B.A., et al. Adverse reactions to allogeneic whole blood donation by 16- and 17-year olds. JAMA 2008, 299:2279-2286.
64. Wiltbank T.B., Giordano G.F., Kamel H., et al. Faint and prefaint reactions n whole-blood donors: An analysis of predonation measurements and their predictive value. Transfusion 2008, 48:1799-1808.
65. Frances C.R., Menitove J.E. Mitigating adverse reactions in youthful donors. Transfusion 2008, 48:1774-1776.
66. Frances C.R., Ditto B., France J.L., et al. Psychometric properties of the blood donation reactions inventory: A subjective measurement of presyncopal reactions to blood donation. Transfusion 2008, 48:1820-1826.
67. Frances C.R., Rader A., Carison B. Donors who react may not come back: Analysis of repeat donation as a function of phlebotomist ratings of vasovagal reactions. Transfus Apher Sci 2005, 33:99-106.
68. Ferguson E., Frances C.R., Abraham C., et al. Improving blood donor recruitment and retention: Integrating theoretical advances from social and behavioral science research agendas. Transfusion 2007, 47:1999-2010.
69. Frances C.R., Montalva R., Frances J.L., et al. Enhancing attitudes and intentions in prospective blood donors: Evaluation of a new donor recruitment brochure. Transfusion 2008, 48:526-530.
70. Kuter D.J. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 2009, 60:193-206.
71. Kuter D.J. New thrombopoietic growth factors. Clin Lymph Myel 2009, 9:S347-S356.
72. Ferreira-González I., Permanyer-Miralda G., Busse J.W., et al. Methodologic discussions for using and interpreting composite endpoints is limited, but still identify major concerns. J Clin Epidemiol 2007, 60:651-657.
73. Freemantle N., Calver M. Weighing the pros and cons for composite outcomes in clinical trials. J Clin Epidemiol 2007, 60:658-659.
74. Delaney M., Meyer E., Lin Y., et al. Improving the reporting of clinical platelet transfusion studies. Transfusion 2010, (in press).
75. Giangregario L., Cook R.J. The role of non-inferiority designs in clinical research. Transfusion 2008, 48:1050-1052.
76. Heddle N.M. The research question. Transfusion 2007, 47:15-17.